AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission
- PMID: 3936350
- PMCID: PMC1684746
AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission
Abstract
The AIMilano apoprotein variant is associated with a marked reduction of high density lipoprotein (HDL) cholesterol levels and with increased triglyceridemia. In spite of the low HDL-cholesterol (HDL-Ch), carriers do not generally show clinical signs of atherosclerosis. The biochemical disorder is linked to a molecular change in apoprotein AI, that is, an arg----cys substitution in the 173 position, thus allowing the formation of AIMilano-AIMilano dimers and AIMilano-AII complexes. The origin of the variant gene has been located in Limone sul Garda, a small community in Northern Italy (about 1,000 individuals). This community has a genetic, biochemical, and clinical individuality, consequent to its isolation up to a few years ago; the citizens show highly uniform alimentary habits and elevated consanguinity. The complete population of the small village was sampled, and, by the use of an analytical isoelectric focusing technique for the detection of the mutant, a total of 33 living carriers, ranging in age from 2 to 81 yrs, were identified. Analysis of the genealogic tree of the complete family groups showed that the apoprotein (apo) AIMilano is transmitted as an autosomal dominant trait, all carriers coming from a single mating couple, living in the eighteenth century. The carriers are heterozygous for the apoprotein variant.
Similar articles
-
Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant.J Biol Chem. 1985 Dec 25;260(30):16321-5. J Biol Chem. 1985. PMID: 3934174
-
Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality.Metabolism. 1981 May;30(5):502-9. doi: 10.1016/0026-0495(81)90188-8. Metabolism. 1981. PMID: 6785551
-
High density lipoprotein-3 heterogeneity in subjects with the apo-AIMilano variant.J Biol Chem. 1982 Sep 10;257(17):9926-30. J Biol Chem. 1982. PMID: 6809752
-
Apolipoproteins of human plasma high density lipoproteins. Biology, biochemistry and clinical significance.Clin Physiol Biochem. 1984;2(2-3):111-22. Clin Physiol Biochem. 1984. PMID: 6435927 Review.
-
Familial hypoalphalipoproteinemias.Clin Invest Med. 1990 Aug;13(4):202-10. Clin Invest Med. 1990. PMID: 2119926 Review.
Cited by
-
Protective alleles and precision healthcare in crewed spaceflight.Nat Commun. 2024 Jul 22;15(1):6158. doi: 10.1038/s41467-024-49423-6. Nat Commun. 2024. PMID: 39039045 Free PMC article. Review.
-
High-Density Lipoprotein-Targeted Therapies for Heart Failure.Biomedicines. 2020 Dec 16;8(12):620. doi: 10.3390/biomedicines8120620. Biomedicines. 2020. PMID: 33339429 Free PMC article. Review.
-
Towns with extremely low mortality due to ischemic heart disease in Spain.BMC Public Health. 2012 Mar 9;12:174. doi: 10.1186/1471-2458-12-174. BMC Public Health. 2012. PMID: 22404881 Free PMC article.
-
Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.Curr Atheroscler Rep. 2005 Mar;7(2):88-94. doi: 10.1007/s11883-005-0029-x. Curr Atheroscler Rep. 2005. PMID: 15727722 Review.
-
Targeting high density lipoproteins in the prevention of cardiovascular disease?Curr Cardiol Rep. 2012 Dec;14(6):684-91. doi: 10.1007/s11886-012-0317-3. Curr Cardiol Rep. 2012. PMID: 22991041 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical